c-Met signaling comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-06-05. Numbers and descriptions here follow the published literature rather than marketing material.
Development of dihexa has been linked to academic research on synaptogenesis, the formation of new synapses. Preclinical studies in rodents have examined its effects on learning and memory tasks. These studies are often cited in discussions about cognitive enhancement, but they do not establish safety or efficacy in humans. The compound's patent and commercial history is limited, and it is not widely available through pharmaceutical channels. Most information comes from animal models and in vitro experiments. Researchers continue to explore its basic biology rather than clinical applications.
Dihexa is not approved for human use in the United States or the European Union. It is commonly sold as a research chemical, a category that may not require the same regulatory review as medicines. Buyers should note that product labels may lack independent verification of identity or purity. The legal status can vary by country, and importation may be restricted. Reliable information about sourcing and quality is often scarce. Scientific publications typically use synthesized material from laboratories rather than commercial consumer products.
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
| Property | Value | Notes |
|---|---|---|
| CAS Registry Number | 1401708-83-5 | Identifier used in chemical databases. |
| Common synonyms | P21; N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) | Names vary by supplier and publication. |
| Physical form | White to off-white powder | Lyophilized solid typical of peptides. |
| Solubility | Soluble in DMSO; limited in water | Aqueous preparation may need a co-solvent. |
| Storage | -20 °C, desiccated, protected from light | Reduce freeze-thaw cycles to maintain stability. |
Regulatory agencies have not approved dihexa as a prescription drug or supplement. In many countries it falls into a gray area when sold for laboratory research. Buyers may encounter products marketed for research use only, which are not intended for human consumption. Purity and identity can vary between suppliers and batches. Certificates of analysis and independent testing are often recommended for research materials. Documentation helps verify what a vial contains.
Discussion of dihexa in online communities sometimes outpaces the scientific record. Anecdotal reports are difficult to verify and may not distinguish effects from placebo or expectation. The absence of approved human data means long-term risks remain unknown. Researchers continue to investigate related compounds and pathways. Open questions include whether animal findings translate to humans and which biological targets matter most. No consensus exists on these points. Current reviews emphasize the need for rigorous clinical research.
Most published work on dihexa consists of preclinical studies using cell cultures or rodents. Reports have described effects on synaptic connectivity and performance on cognitive tasks in some animal models. These findings are generally presented as preliminary and require independent replication. Study designs, doses, and outcome measures vary across experiments, which complicates direct comparison. No large controlled human trials have established efficacy or safety for any medical use. At present, the evidence base is limited.
The leading hypothesis for dihexa centers on hepatocyte growth factor (HGF) and its receptor, c-Met. In cell-based assays, dihexa has been reported to potentiate HGF-dependent signaling. That pathway influences cell growth, survival, and motility. Because c-Met signaling is widespread, the proposed mechanism is broad rather than specific to neurons. The exact binding site and stoichiometry remain areas of active investigation, and independent replication is limited. This uncertainty limits firm conclusions about how the compound acts in living organisms.
Animal studies have examined dihexa in models of cognitive impairment, synaptic plasticity, and memory. Some reports describe improved performance on maze or avoidance tasks after administration. These findings are preclinical and often involve small samples, varied routes, and differing formulations. Results in rodents do not establish effects in humans. The absence of published randomized controlled trials in people is a major gap in the evidence base. Observational reports and user accounts do not substitute for controlled clinical data.
Discussion in the literature often separates direct receptor activation from downstream growth-factor modulation. Dihexa is not simply an angiotensin receptor blocker or a classic nootropic drug. Its proposed action may depend on endogenous HGF levels, which vary by tissue and physiological state. Questions remain about brain penetration, metabolic stability, and active metabolites. Reviews note that mechanistic claims should be treated as hypotheses until supported by independent studies. That distinction is important when interpreting promotional claims or early laboratory findings.
Laboratory characterization of dihexa typically relies on reverse-phase high-performance liquid chromatography for purity and mass spectrometry for identity. These methods are standard for synthetic peptides and help distinguish the target compound from related impurities or degradation products. Because dihexa is a small peptide-like molecule, it may be susceptible to hydrolysis under certain conditions. Storage recommendations generally emphasize low temperature, dryness, and protection from light. Analytical certificates from suppliers vary in detail, so independent verification can be important for research use.
Reported effects of dihexa are often described in terms of synaptogenesis, a process by which neurons form new synaptic connections. This concept is biologically plausible but difficult to measure directly in living humans. Animal behavioral tests can suggest memory or learning changes, yet such tests have limitations and may not translate to people. The literature includes conflicting or incomplete findings, and some studies are small. As a result, the mechanism remains a subject of investigation rather than a settled explanation.
The proposed mechanism of dihexa involves activation of hepatocyte growth factor and its receptor, c-Met. In cell models, this signaling pathway is associated with dendritic spine formation and synaptic reorganization. Dihexa is described as a stabilized analog of angiotensin IV, which also interacts with related systems. However, the precise binding profile and downstream effects remain incompletely characterized. Most mechanistic evidence comes from in vitro assays and rodent studies rather than human trials.
Chick-fil-A, Inc. ( CHIK-fil-AY, a play on the American English pronunciation of "filet") is an American fast food restaurant chain and the largest chain specializing in chicken sandwiches. Headquartered in College Park, Georgia, Chick-fil-A operates restaurants across 48 states, as well as in the District of Columbia and Puerto Rico. The company also has operations in Canada, the United Kingdom, and Singapore, and previously had restaurants in South Africa. The restaurant has a breakfast, a lunch, and a dinner menu. The chain also provides catering services. Chick-fil-A calls its specialty the "original chicken sandwich". It is a piece of deep-fried breaded boneless chicken breast served on a toasted bun with two slices of dill pickle, or with lettuce, tomato, and cheese. Many of the company's values are influenced by the Christian religious beliefs of its late founder, S. Truett Cathy (1921–2014), a devout Southern Baptist. Reflecting a commitment to Sunday Sabbatarianism, all Chick-fil-A restaurants are closed for business on Sundays, and Christmas Day, as well as Thanksgiving for US and Canadian locations. The company's conservative opposition to same-sex marriage has caused controversy; the company began to loosen its stance on this issue from 2019. Even among numerous controversies and boycott attempts, the 2022 American Customer Satisfaction Index found that Chick-fil-A remained the country's favorite fast food chain for the eighth consecutive year, and it has the highest per store sales of any fast food chain in the nation.
Once all the eggs are secured in the nest, the pair will spawn again. If more than one female is present in the breeding tank, the male may spawn with all of them. The spawning sessions will continue for two to four hours, and produce between 300 and 800 eggs. Dwarf gouramis have a fecundity of about 600 eggs.[1] Upon completion, the male will place a fine layer of bubbles beneath the eggs, assuring that they remain in the bubble nest. The male will protect the eggs and fry. In 12 to 24 hours the fry will hatch, and continue developing within the protection of the bubble nest. After three days they are sufficiently developed to be free swimming and leave the nest. When the fry are two to three days old the male should also be removed or he may consume the young. After spawning the female should be moved to a different tank. The male will now take sole responsibility for the eggs, aggressively defending the nest and surrounding territory. When first hatched, the tiny fry should be fed infusoria, and later, brine shrimp and finely ground flakes. Freeze-dried tablets may also be fed to older fry.
== Safety == The safety of ketosis from low-carbohydrate diets is often called into question by clinicians, researchers and the media. A common safety concern stems from the misunderstanding of the difference between physiological ketosis and pathologic ketoacidosis. There is also continued debate whether chronic ketosis is a healthy state or a stressor to be avoided. Some argue that humans evolved to avoid ketosis and should not be in ketosis long-term. The counter-argument is that there is no physiological requirement for dietary carbohydrates, as adequate energy can be made via gluconeogenesis and ketogenesis indefinitely. Alternatively, the switching between a ketotic and fed state has been proposed to have beneficial effects on metabolic and neurologic health. The effects of sustaining ketosis for up to two years are known from studies of people following a strict ketogenic diet for epilepsy or type 2 diabetes; these include short-term adverse effects leading to potential long-term ones. However, literature on longer term effects of intermittent ketosis is lacking.
Sources: en.wikipedia.org
Thus, the two substrates of this enzyme are N-acyl-L-amino acid and H2O, whereas its two products are carboxylate and L-amino acid. This enzyme belongs to the family of hydrolases, those acting on carbon-nitrogen bonds other than peptide bonds, specifically in linear amides. The systematic name of this enzyme class is N-acyl-L-amino acid amidohydrolase. Other names in common use include dehydropeptidase II, histozyme, hippuricase, benzamidase, acylase I, hippurase, amido acid deacylase, L-aminoacylase, acylase, aminoacylase I, L-amino-acid acylase, alpha-N-acylaminoacid hydrolase, long acyl amidoacylase, and short acyl amidoacylase. This enzyme participates in urea cycle and metabolism of amino groups.
ADP-ribose is an intermediate that is produced during the metabolism of NAD+, mono- or poly-unsaturated proteins, and cyclic-ADP ribose. ADP-ribose is a protein-glycating agent, and excess levels of ADP-ribose in the cell can cause non-enzymatic ADP-ribosylation. Non-enzymatic ADP-ribosylation can inactivate protein targets that contain nucleotide-binding sites when the adenylate moiety of ADP-ribose binds to them, and it can also interfere with metabolic regulation that occurs via enzymatic ADP-ribosylation. For example, actin polymerization is inhibited by non-enzymatic ADP-ribosylation at a Cys residue. Thus, it is believed that ADPRase functions in general as a house-cleaning enzyme to eliminate potentially deleterious ADP-ribose from the cell. In the literature, the detoxifying role of ADPRase is directly supported in E. coli cells. But in mammalian cells, there is only an indirect evidence linking ADPRase to a detoxifying role, and this comes from studies of the very specific rat liver ADPRibase-I by cytotoxic agents.
== Formation and decay == The sum of the atomic mass of the two atoms produced by the fission of one fissile atom is always less than the atomic mass of the original atom. This is because some of the mass is lost as free neutrons, and once kinetic energy of the fission products has been removed (i.e., the products have been cooled to extract the heat provided by the reaction), then the mass associated with this energy is lost to the system also, and thus appears to be "missing" from the cooled fission products. Since the nuclei that can readily undergo fission are particularly neutron-rich (e.g. 61% of the nucleons in uranium-235 are neutrons), the initial fission products are often more neutron-rich than stable nuclei of the same mass as the fission product (e.g. stable zirconium-90 is 56% neutrons compared to unstable strontium-90 at 58%). The initial fission products therefore may be unstable and typically undergo beta decay to move towards a stable configuration, converting a neutron to a proton with each beta emission. (Most fission products do not decay via alpha decay.) A few neutron-rich and short-lived initial fission products decay by ordinary beta decay (this is the source of perceptible half-life, typically a few tenths of a second to a few seconds), followed by immediate emission of a neutron by the excited daughter-product. This process is the source of so-called delayed neutrons, which play an important role in control of a nuclear reactor. The first beta decays are rapid and may release high energy beta particles or gamma radiation.
=== Via neopinone === If the enol ether in thebaine is converted to a ketone by thebaine 6-O-demethylase, a methyl group leaves as formaldehyde, with the oxidation driven by molecular oxygen activated as a ferryl group Fe(IV)=O.
Sources: en.wikipedia.org
In August 2012, Domino's Pizza changed its name to simply Domino's. At the same time, Domino's introduced a new logo that removed the blue rectangle and text under the domino in the logo, and changed the formerly all-red domino to be blue on the side with two dots and red on the side with one dot. This was done because the company wanted to "expand" menu choices rather than simply rely on its traditional pizza. In April 2022, Domino's Italy franchise operator EPizza SpA filed for bankruptcy at a Milan court after two years of declining sales caused by the COVID-19 lockdowns in Italy. In addition, Domino's Pizza faced competition from local pizza chains and restaurants, which had begun using food delivery app services such as Glovo, Just Eat and Deliveroo. The reason for the failure, however, is mainly that the customer rating of Domino's outlets is very low in Italy, which explains the difficulty of competing with the high quality of Italian pizzas. After the 90-day grace period expired in July 2022, Domino's closed all its Italian stores on 20 July. In 2023, following the Russian invasion of Ukraine, Domino's Russian operations also filed for bankruptcy and Domino's ultimately announced their withdrawal from the country, closing down all of their restaurants shortly after the announcement. On December 12, 2024, Domino's announced that it would transfer its stock to the Nasdaq Global Select Market which took effect on January 2, 2025 at the stock market open. The company retained the ticker symbol "DPZ".
With insect stings, a large local reaction may occur as an area of skin redness greater than 10 cm in size that can last one to two days. This reaction may also occur after immunotherapy. The skin forms an effective barrier to the entry of most allergens, but this barrier cannot withstand everything. For example, an insect sting can breach the barrier and inject allergen into the affected spot. When an allergen enters the epidermis or dermis, it triggers a localized allergic reaction which activates the mast cells in the skin resulting in an immediate increase in permeability of blood vessels, leading to fluid leakage and swelling in the affected area. Mast-cell activation also stimulates a skin lesion called the wheal-and-flare reaction. Then the release of chemicals from local nerve endings by a nerve axon reflex causes the widening of surrounding cutaneous blood vessels, which causes redness of the surrounding skin. As part of the allergic response, the body has developed a secondary response that, in some individuals, causes a more widespread and sustained skin swelling. This usually occurs about 8 hours after the allergen originally comes in contact with the skin. When an allergen is ingested, a dispersed form of wheal-and-flare reaction, known as urticaria or hives, will appear when the allergen enters the bloodstream and eventually reaches the skin. This same skin reactivity allows allergists to test for existing allergies by injecting a small amount of an allergen into the skin, which causes a reaction at the injection site.
It is a member of the small pentraxins family (also known as short pentraxins). The polypeptide encoded by this gene has 224 amino acids. The full-length polypeptide is not present in the body in significant quantities due to signal peptide, which is removed by signal peptidase before translation is completed. The complete protein, composed of five monomers, has a total mass of approximately 120,000 Da. In serum, it assembles into stable pentameric structure with a discoid shape.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide investigated in preclinical research. It is often classified as an angiotensin IV analog or an HGF mimetic. It is not an approved medicine.
No. Regulatory agencies have not approved dihexa for human use. It is sold as a research chemical in some markets, and human safety and efficacy data are lacking.
Laboratory studies have examined its effects on synapse formation and cognitive tasks in animals. These are early-stage findings. They do not prove benefits or safety in people.
Dihexa is a synthetic peptide analog related to angiotensin IV. It is studied in preclinical research for effects on neural signaling and synapse formation. It is not an approved medicine.